Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Alcon (ALC) reported third-quarter 2026 sales of $2.7 billion, up 5% from the same quarter a year earlier. Diluted earnings per share rose 13% to $0.54, while core diluted EPS, a non-IFRS adjusted measure, increased 15% to $0.91. Operating margin reached 14.0%, versus 12.8%, with results benefiting from $58 million in tariff refunds. Implantables sales fell 2% amid U.S. competitive pressure, while consumables, equipment and Vision Care categories grew.
For the first nine months, sales rose 7% to $8.2 billion, but diluted EPS fell 40% to $0.92. Discontinuing the PowerVision programs generated a $402 million pre-tax, non-cash net charge. Operating cash flow reached $1.689 billion, versus $1.613 billion. Alcon returned $748 million through dividends and repurchases year to date and recently announced the acquisition of Neurotech Pharmaceuticals.
Alcon (ALC) has acquired Neurotech Pharmaceuticals for $550 million, adding the eye disease treatment ENCELTO to its retina portfolio. ENCELTO is the only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, a rare retinal disease that causes irreversible central vision loss. The cell therapy is surgically implanted inside the eye; it received FDA approval in March 2025 and is currently available only in the U.S.
Alcon may be required to make additional contingent payments, including upon achievement of commercial milestones. The company expects the transaction to modestly add to net sales growth, slightly reduce core diluted earnings per share in 2027, and increase that earnings measure thereafter. Alcon also expects its surgical retina presence and expertise to accelerate commercialization and patient access.
Alcon (ALC) received U.S. Food and Drug Administration approval for BRYTLY Redness Reliever Eye Drops, an over-the-counter option for eye redness. The approval expands Alcon’s consumer eye care portfolio. Alcon expects availability at major retailers nationwide and online in the coming months, with additional markets to follow in the future.
One drop reduces redness within one minute, with results lasting up to 12 hours. Alcon’s claim that BRYTLY lasts up to 50% longer than Lumify is based on label durations: up to 12 hours versus up to eight hours, rather than a stated head-to-head trial. BRYTLY contains no bleaches or dyes. Studies demonstrated a low risk of redness rebound and tachyphylaxis, or reduced response with repeated use, when used as directed.
Alcon (ALC) launched Systane PRO Preservative-Free eye drops in Canada, which it says relieve dry eye symptoms for up to 12 hours.
The multi-dose formula contains HP-guar, hyaluronic acid, nano-sized lipids and propylene glycol. Alcon describes it as hydrating, restoring and protecting against dryness across all types of dry eye. It is now available in Canada and is the longest-lasting dry eye symptom relief drop in the Systane range.
The duration claim has a qualification: 47% of patients experienced meaningful symptom relief at 12 hours in a group of 153. A cited tear-film stability measure improved at Day 30 versus baseline with four daily doses (N=316; p<0.0001). The release also specifies four daily doses for its long-lasting lubrication claim.
Alcon (ALC) announced the initial commercial launch of UNITY M, a premium ophthalmic surgical microscope delivering precise control for eye surgeons in select markets including the U.S. and Japan.
UNITY M is the latest device on the UNITY platform, combining advanced optics, modular architecture and practice-specific customization. The base model offers an industry-described red reflex zone up to 6x larger than Zeiss ARTEVO, Color Tunable Illumination described as the first and only of its kind in microscopes, and an optimized depth of field for uninterrupted visualization during surgery. UNITY M has obtained CE Mark and regulatory approvals in India, Europe, Canada, Japan and the U.S., with inventory expected to begin shipping in September and broader rollout to Europe and additional markets to follow.
Alcon (SIX/NYSE: ALC) has priced a public offering of EUR 500 million aggregate principal amount of 3.875% senior notes due 2033. The notes will be issued by Alcon Finance Corporation and fully and unconditionally guaranteed on a senior basis by Alcon. Application has been made for listing and trading on the Luxembourg Stock Exchange’s Euro MTF. The offering is expected to close on September 2, 2026, subject to customary conditions, and proceeds are intended for general corporate purposes, including potential refinancing of existing Group debt.
Alcon (NYSE:ALC) reported second-quarter 2026 sales of $2.8 billion, up 8% reported and 7% in constant currency versus 2025, driven by growth across Surgical and Vision Care. Core operating margin rose to 20.6% and core diluted EPS increased to $0.84 from $0.76.
Reported operating income fell to $11 million and diluted EPS to $0.00, mainly due to a $402 million pre-tax, non-cash charge tied to discontinuation of the PowerVision IOL programs after unfavorable clinical outcomes. First-half net sales were $5.5 billion (+9% reported), free cash flow was $693 million, and year-to-date shareholder returns via dividends and buybacks totaled $538 million. According to Alcon, full-year guidance was updated, raising expected core operating margin and core diluted EPS growth.
Alcon (NYSE:ALC) reported first-quarter 2026 sales of $2.7 billion, up 10% reported and 6% constant currency. Reported diluted EPS was $0.39; core diluted EPS was $0.85. Operating income fell to $292 million and operating margin to 10.9%. The board approved a CHF 0.28 dividend and a $1.5 billion share repurchase authorization over three years. The company maintained 2026 net sales and core margin outlooks and updated core diluted EPS growth to +10% to +13% (cc). Webcast scheduled May 6, 2026.
Alcon (SIX/NYSE: ALC) reported that shareholders approved all resolutions at the 2026 Annual General Meeting on April 30, 2026.
Key outcomes: CHF 0.28 gross dividend per dividend-bearing share declared; F. Michael Ball re-elected Chair; R. Scott Herren elected to the Board; statutory auditors and independent representative re-elected; 2025 financial and non-financial reports accepted.
Alcon (NYSE:ALC) announced that Systane is the official eye drop of the Toronto Blue Jays, a partnership launching April 7, 2026 to raise dry eye awareness across Canada. The program features stadium activations, digital experiences and national initiatives to educate fans about dry eye symptoms and management.